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   ABSTRACT   
  Objectives      Past studies have reported conﬂ  icting 
rates of venous thrombotic events (VTEs) in rheumatoid 
arthritis (RA). The current study aimed to compare (1) the 
rates of VTEs in patients with RA treated with anti-tumour 
necrosis factor (anti-TNF) therapy versus those treated 
with non-biological disease-modifying antirheumatic 
drugs (nbDMARDs) alone and (2) the rates between each 
individual anti-TNF agent and nbDMARDs.   
  Methods      Using data from the British Society for 
Rheumatology Biologics Register, a national prospective 
observational cohort study of biological safety in patients 
with RA, the authors compared the incidence of VTEs 
between 11 881 anti-TNF- and 3673 nbDMARD-treated 
patients. Analysis was limited to the ﬁ  rst VTE per person. 
HRs were calculated using Cox modelling. Adjustment 
was made for potential confounders including surgery 
performed during follow-up.   
  Results      A total of 196 ﬁ  rst VTEs were reported (151 
anti-TNF, 45 nbDMARD). Overall there was no difference 
in the rates of VTEs between anti-TNF- and nbDMARD-
treated patients (adjusted HR 0.8 (95% CI 0.5 to 1.5)). 
The risk was similar across all anti-TNF agents. Rates of 
postoperative VTEs did not signiﬁ  cantly differ between 
groups.  
  Conclusions      These data suggest that anti-TNF therapy 
is not associated with an increased risk of VTEs in RA 
patients.      
  INTRODUCTION 
  Rheumatoid arthritis (RA) is associated with 
increased mortality and co-morbidity compared 
with the general population.  1     2   RA patients may 
have an increased risk of developing venous throm-
botic events (VTEs), based on the high prevalence 
of many known VTE risk factors.  3     4   Studies exam-
ining the incidence of VTEs in patients with RA 
have been discordant.  5     6   
  The introduction of anti-tumour necrosis fac-
tor (anti-TNF) drugs for the treatment of RA has 
improved the outcomes of RA dramatically.  7    –    9   
However, there remain concerns about their long-
term safety. Case reports  10     11   and retrospective 
studies  12    –    15   looking at VTEs in anti-TNF-treated RA 
patients have produced conﬂ  icting results. 
  To study this further, the current analysis aimed 
to compare (1) the rates of VTEs in RA patients 
treated with anti-TNF and non-biological disease-
modifying antirheumatic drugs (  nbDMARDs) 
and (2) the rates between the individual anti-TNF 
agents and nbDMARDs.   
  METHODS 
  A full description of the methods relating to this 
analysis is available in our publication examining 
the risk of septic arthritis in this same cohort.  16   
  In brief, the British Society for Rheumatology 
Biologics Register (BSRBR) is a national prospective 
cohort study that was established in 2001. Patients 
with active RA who were starting treatment with 
anti-TNF therapy were enrolled for observational 
follow-up. Three anti-TNF agents were currently 
in use during the study period analyses: etanercept 
(ETN), inﬂ   iximab (INF) and adalimumab (ADA). 
A comparison cohort of RA patients with active 
disease currently receiving an nbDMARD was 
recruited and followed up in parallel. 
  Baseline information was collected regarding 
demographics, disease severity and co-morbidity. 
There were three sources of data collection dur-
ing follow-up: consultant questionnaires, patient 
questionnaires and diaries, and the UK national 
cancer and death register (National Health Service 
Information Centre). 
  Adverse events from these sources were coded 
using MedDRA (the Medical Dictionary for 
Regulatory Activities). 
  Deﬁ  nition of outcome 
  This analysis limited outcomes to the ﬁ  rst VTE per 
person. All events were veriﬁ  ed by a BSRBR physi-
cian (JG) according to prespeciﬁ  ed criteria (online 
supplementary table 1). VTEs were classiﬁ  ed  as 
postoperative if they occurred within 90 days of 
any surgery.   
  Statistical  methods 
  Patients in the anti-TNF cohort were considered to 
be exposed from the date ﬁ  rst treated with an anti-
TNF drug until the ﬁ  rst VTE, most recent follow-up, 
ﬁ   rst missed dose of anti-TNF therapy or death. 
We did not include a 90-day lag window after the 
ﬁ  rst missed dose in our primary analysis model as 
we felt that the effect of anti-TNF therapy upon 
thrombosis risk would cease after the drug had 
been eliminated from the body. For patients in the 
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comparison cohort, follow-up started at the time of registration 
until ﬁ  rst VTE, most recent follow-up form   or death. Incidence 
rates of VTEs are presented as events per 1000 person years (pyrs) 
with 95% CIs. Survival analyses, performed using a Cox propor-
tional hazards model, were used to compare the rates of VTEs 
between cohorts. Inverse probability of treatment weighting  16   
was used to adjust for confounding between the groups, includ-
ing age and gender, disease severity (baseline 28-joint Disease 
Activity Score and Health Assessment Questionnaire), disease 
duration, year of entry into the study, use of baseline steroids, 
smoking status and co-morbidity (hypertension, chronic lung 
disease and diabetes). Surgery was entered into the model as a 
time-varying covariate, with patients considered to be at risk for 
90 days postprocedure. An additional analysis evaluated the risk 
of postoperative VTEs using logistic regression to compare the 
risk of VTEs following surgery. Patients could contribute multi-
ple surgeries to this analysis. Adjustment was made for the same 
confounders used in the main analysis. For all analyses, missing 
baseline data were replaced using multiple imputations.  16   All 
analyses were performed using Stata V.10 software (StataCorp, 
College Station, Texas, USA).     
  RESULTS 
  This analysis included 15 554 patients (11 881 anti-TNF, 3673 
nbDMARD cohort). The anti-TNF cohort comprised 4139 
patients starting ETN, 3475 patients starting INF and 4267 
patients starting ADA. The baseline characteristics are displayed 
in   table 1  , which shows that the anti-TNF cohort was younger 
and comprised proportionally more women. The anti-TNF 
cohort also had more severe disease of a longer duration and 
had greater exposure to steroids at baseline.   
  There were 196 veriﬁ  ed VTEs (anti-TNF: 151, nbDMARD: 45) 
with an overall crude incident rate of 3.7 (95% CI 3.1 to 4.3)/1000 
pyrs and 3.9 (95% CI 2.9 to 5.3)/1000 pyrs, respectively. The 
unadjusted HR was 1.1 (95% CI 0.8 to 1.6) and fully adjusted 
HR was 0.8 (95% CI 0.5 to 1.5) (  table 2  ). We conducted sensitiv-
ity analyses to calculate HRs in those on drugs with a 90-day lag 
window, which did not alter the results (online supplementary 
table 2). Supplementary data are available detailing univariate 
predictors of VTEs and HRs for unimputed data (online supple-
mentary tables 3–5).   
  When comparing the anti-TNF agents, the crude incidence of 
VTEs was highest in the INF group at 4.7 events per 1000 pyrs, 
compared with 3.3 for ADA- and ETN-treated patients. After 
adjusting for confounders, none of the hazard estimates for the indi-
vidual anti-TNF agents differed signiﬁ  cantly from the   nbDMARD 
cohort (  table 2  ). Analyses comparing individual anti-TNF agents 
with each other also showed no signiﬁ  cant differences. 
  In total (allowing multiple surgeries per patient), 5584 sur-
gical operations were reported during follow-up (  table 3  ). 
Orthopaedic procedures accounted for 3948 (71%) of the surger-
ies performed. Twenty-one surgeries were complicated by a VTE 
(anti-TNF: 18/4572, nbDMARD: 3/1012). The fully adjusted OR 
for postoperative VTEs in the anti-TNF cohort compared with 
the nbDMARD cohort was 1.9 (95% CI 0.5 to 7.4) (  table 3  ). A 
sensitivity analysis limited to orthopaedic procedures showed 
similar ﬁ  ndings (results not shown).     
  DISCUSSION 
  The data from this BSRBR cohort have shown that treatment 
with ETN, INF or ADA was not associated with a change in 
the risk of ﬁ  rst VTE, either de novo or in the postoperative 
period. 
  This cohort had over 90% power to detect a doubling in the 
risk of VTEs but only 60% power to detect a 50% increase in the 
anti-TNF cohort compared with the DMARD cohort. Therefore, 
although we are conﬁ  dent that we can exclude a doubling in 
risk of VTEs with the TNF inhibitors studied here, differences 
of a smaller magnitude cannot be excluded. However, given the 
incidence of VTEs was 3.7/1000 pyrs in the nbDMARD cohort, 
smaller differences would be of questionable clinical relevance. 
For example, a 50% increase in relative risk would represent a 
small risk in absolute terms, equivalent to a number needed to 
treat one additional event of 540. 
  Comparing rates of events between the three anti-TNF 
cohorts must be done with caution. For example, it is important 
to acknowledge that differences exist relating to recruitment of 
patients to the anti-TNF cohorts by calendar year.  17   This could 
be of particular relevance if we were to compare differences in 
the rates of postoperative VTEs when variations in rates could be 
partly explained by changes in the prescribing of anticoagulants 
following high-risk procedures. However, accepting the limita-
tions of between-drug comparisons, our data show that the risk 
between ETN, INF and ADA for VTEs is broadly comparable. 
  The rates of postoperative VTEs in this cohort were reassur-
ing, with approximately 4 out of every 1000 procedures being 
complicated by VTEs in all cohorts. Although the OR for post-
operative VTEs for the anti-TNF cohort was 1.9, the 95% CI 
was wide and this result should not be interpreted as a signiﬁ  -
cant ﬁ  nding. Research into this possible association could be 
explored further in countries with access to national registers of 
surgical procedures. 
 Table  1     Baseline characteristics of the nbDMARD- and anti-TNF-treated patients   
 Characteristic 
 nbDMARD 
n=3673 
 Anti-TNF 
n=11 881   p  Value   ETN  n=4139   INF  n=3475   ADA  n=4267   p  Value 
Age, mean (SD)   60 (12)    56 (12)    0.0001    56 (12)    56 (12)    57 (12)    0.0184 
Gender,  %  female  72   76   <0.0001   77   76   76   0.203 
Disease duration, median (IQR) years 6 (1–15) 11 (6–19) 0.0001 12 (6–19) 12 (6–19) 10 (5–18)   0.0001 
DAS28 score, mean (SD) 5.1 (1.3) 6.6 (1.0) 0.0001 6.6 (1.0) 6.6 (1.0) 6.5 (1.0)   0.0001 
HAQ score, mean (SD) 1.5 (0.8) 2.0 (0.6) 0.0001 2.1 (0.6) 2.1 (0.5) 2.0 (0.6)   0.0001 
Corticosteroids, no. (%) 837 (23) 5, 252 (44) <0.0001 1979 (48) 1609 (46) 1664 (39)   <0.0001 
Diabetes, no. (%)   247 (7)    685 (6)    0.033    255 (6)    169 (5)    261 (6)    0.026 
Hypertension, no. (%)   1171 (32)    3563 (30)    0.041    1283 (31)    966 (28)    1314 (31)    0.002 
Smoking history, no. (%)       0.001          0.056 
  Current  smoker  868  (24)   2580  (22)     846  (21)   757  (22)   977    (24)   
  Former smoker   1454 (40)    4510 (38)      1576 (38)    1314 (38)    1620 (38)   
 Never  smoked  1333  (36)   4714  (40)     1691  (41)   1386  (40)   1637  (39)   
      ADA, adalimumab; Anti-TNF, anti-tumour necrosis factor; DAS28, 28-joint Disease Activity Score; ETN, etanercept; HAQ, Health Assessment Questionnaire; INF, inﬂ  iximab; nbDMARD, 
non-biological disease-modifying antirheumatic drug.     
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  The main strengths of the BSRBR data have been detailed pre-
viously  18   and relate to the prospective nature of the study, the 
large size of the cohort and the detailed data collection during 
follow-up. Several important limitations must also be consid-
ered when interpreting these results. The observational nature 
of the BSRBR predisposes to channelling bias, whereby patients 
with more severe disease are more likely to be enrolled into 
the anti-TNF cohort. Although we have made extensive efforts 
to adjust for this, we must acknowledge that it is likely some 
unmeasured confounding persists. In particular, we have only 
made adjustment for confounders that we record at baseline. 
Disease severity and steroid exposure are examples of variables 
that we would predict to change signiﬁ  cantly during follow-up. 
Higher disease activity may well represent a prothrombotic 
state and would be likely to correlate to immobility; therefore, 
correct adjustment for this factor is clearly important. Further 
research is needed to establish how best we should take these 
factors into account. 
  In conclusion, this study found no evidence that anti-TNF ther-
apy is associated with an increased risk of VTEs in RA patients, 
with no difference in risk observed between the anti-TNF drugs. 
Although this is a negative study, it has important implications. 
These results strengthen the evidence base and will help enable 
patients and healthcare professionals to make informed choices 
regarding therapy. 
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 Table  2     Crude incidence rates and hazard rates of veriﬁ  ed ﬁ  rst VTE in nbDMARD and anti-TNF-treated 
patients  
 
 nbDMARD 
n=3673 
 Anti-TNF 
n=11 881   ETN  n=4139   INF  n=3475   ADA  n=4267 
Exposure (person years) 11 424 41 235 17 977 10 484 12 773
Total VTEs, n 45 151 60 49 42
VTE incidence rate/1000 
person years (95% CI)
3.9 (2.9 to 5.3) 3.7 (3.1 to 4.3) 3.3 (2.5 to 4.3) 4.7 (3.5 6.2) 3.3 (2.4 to 4.4)
Unadjusted HR (95% CI) Ref 1.1 (0.8 to 1.6) 1.0 (0.7 to 1.6) 1.4 (0.9 to 2.1) 1.0 (0.6 to 1.5)
Adjusted HR (95% CI)  *  Ref 0.8 (0.5 to 1.5) 0.8  †   (0.4 to 1.4) 1.1  †   (0.6 to 1.9) 0.8  †   (0.4 to 1.4)
      ADA, adalimumab; Anti-TNF, anti-tumour necrosis factor; ETN, etanercept; INF, inﬂ  iximab; nbDMARD, non-biological disease-
modifying antirheumatic drug; VTE, venous thrombotic event.   
    *    Inverse probability of treatment weighting model adjusted for age, gender, diabetes, baseline steroid exposure, smoking, 
hypertension, disease duration, disease severity, year of ﬁ  rst anti-TNF drug and year of entry into study, with surgery as a time-
varying covariate.   
  †    Differences between INF and ETN rates were non-signiﬁ  cant (p=0.186). Differences between INF and ADA rates were non-
signiﬁ   cant  (p=0.105).   
 Table  3     Surgery  table  
   nbDMARD   Anti-TNF   ETN   INF   ADA 
Total  surgeries  (n)  1012   4572   2074   1170   1328 
  Total  orthopaedic  (n)  599   3349   1535   859   955 
No. of patients having 
surgery (n)
 699   2816   1184   743   889 
  Orthopaedic  (n)  424   2104   908   546   650 
Patients with more than one 
surgery (n)
 227   1051   486   266   299 
  Orthopaedic  (n)  129   726   334   178   214 
No. postoperative VTEs (n) 3 18 6 6 6
Postop VTE crude rates 
(95% CI)
3.0 (0 to 6.3) 4.0 (2.1 to 5.8) 2.9 (0.6 to 5.2) 5.1 (1.0 to 9.3) 4.5 (0.9 to 8.2)
Unadjusted OR (95% CI)   Referent  1.3 (0.4 to 4.5)   –    –    – 
Fully adjusted OR (95% CI)  *   Referent  1.9 (0.5 to 7.4)  –   –   – 
      *    Adjusted for age, gender, diabetes, baseline steroid exposure, smoking, hypertension, disease duration, disease severity, year 
of ﬁ  rst anti-TNF drug and year of entry into study.   
    ADA, adalimumab; Anti-TNF, anti-tumour necrosis factor; ETN, etanercept; INF, inﬂ  iximab; nbDMARD, non-biological disease-
modifying antirheumatic drug; VTE, venous thrombotic event.     
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